A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors
Public ClinicalTrials.gov record NCT06264921. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1, First-in-Human, Open-Label Study to Evaluate the Safety, Tolerability, PK, and Preliminary Anti-tumor Activity of the Novel Orally Available CDK2 Inhibitor NKT3447 in Adults With Advanced/Metastatic Solid Tumors
Study identification
- NCT ID
- NCT06264921
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- NiKang Therapeutics, Inc.
- Industry
- Enrollment
- 23 participants
Conditions and interventions
Conditions
- Advanced Endometrial Carcinoma
- Advanced Gastric Carcinoma
- Advanced Ovarian Carcinoma
- Advanced Solid Tumor
- CCNE1 Amplification
- Endometrial Cancer
- Endometrial Diseases
- Endometrial Neoplasms
- Gastric Cancer
- Hormone Receptor Negative Breast Carcinoma
- Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
- Metastatic Endometrial Cancer
- Metastatic Endometrial Carcinoma
- Metastatic Gastric Cancer
- Metastatic Gastric Carcinoma
- Metastatic Ovarian Carcinoma
- Metastatic Tumor
- Ovarian Cancer
- Ovarian Carcinoma
- Ovarian Neoplasms
- Platinum-refractory Ovarian Carcinoma
- Platinum-resistant Ovarian Cancer
- Progesterone-receptor-positive Breast Cancer
- Small Cell Lung Carcinoma
- Small-cell Lung Cancer
- Solid Tumor
- Solid Tumor, Adult
- Triple Negative Breast Cancer
- Triple Negative Breast Neoplasms
Interventions
- NKT3447 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 22, 2024
- Primary completion
- Apr 6, 2025
- Completion
- Apr 15, 2025
- Last update posted
- Sep 24, 2025
2024 – 2025
United States locations
- U.S. sites
- 8
- U.S. states
- 8
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California San Francisco (UCSF) - Helen Diller Family Comprehensive Cancer Center | San Francisco | California | 94158 | — |
| Sarah Cannon Research Institute at HealthONE | Denver | Colorado | 80218 | — |
| AdventHealth Cancer Institute | Celebration | Florida | 34747 | — |
| Augusta University Georgia Cancer Center | Augusta | Georgia | 30909 | — |
| Norton Cancer Institute - Broadway | Louisville | Kentucky | 40202 | — |
| The Gabrail Pharmacology Phase 1 Research Center | Canton | Ohio | 44718 | — |
| Texas Oncology-Austin Midtown NEXT Oncology | Austin | Texas | 78758 | — |
| START Mountain Region | West Valley City | Utah | 84119 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06264921, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 24, 2025 · Synced May 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06264921 live on ClinicalTrials.gov.